Back غلوكاغون (دواء) Arabic Glucagón (medicación) Spanish Glukagoi (sendagaia) Basque گلوکاگون (دارو) Persian גלוקגון (תרופה) HE ଗ୍ଲୁକାଗନ (ଔଷଧ) OR Glucagon (dược phẩm) Vietnamese
&sq=Albert Einstein&lang=en&file=File:Glucagon_stereo_animation.gif) | |
| Clinical data | |
|---|---|
| Trade names | Glucagen, Baqsimi, Gvoke, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682480 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Nasal, intravenous (IV), intramuscular injection (IM), subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C153H225N43O49S |
| Molar mass | 3482.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Glucagon, sold under the brand name Baqsimi among others, is a medication and hormone.[9] As a medication it is used to treat low blood sugar, beta blocker overdose, calcium channel blocker overdose, and those with anaphylaxis who do not improve with epinephrine.[10] It is given by injection into a vein, muscle, or under the skin.[10] A version given in the nose is also available.[11]
Common side effects include vomiting.[10] Other side effects include low blood potassium and low blood pressure.[9] It is not recommended in people who have a pheochromocytoma or insulinoma.[10] Use in pregnancy has not been found to be harmful to the baby.[12] Glucagon is in the glycogenolytic family of medications.[10] It works by causing the liver to break down glycogen into glucose.[10]
Glucagon was approved for medical use in the United States in 1960.[10] It is on the World Health Organization's List of Essential Medicines.[13] It is a manufactured form of the glucagon hormone.[10] A generic version became available in the United States in December 2020.[14]
- ^ "Glucagon Use During Pregnancy". Drugs.com. 16 October 2019. Retrieved 16 May 2020.
- ^ "Baqsimi Product information". Health Canada. Retrieved 30 March 2024.
- ^ "GlucaGen Hypokit 1 mg - Summary of Product Characteristics (SmPC)". (emc). 15 June 2015. Retrieved 16 May 2020.
- ^ "Glucagon kit". DailyMed. Retrieved 27 February 2021.
- ^ "Baqsimi- glucagon powder". DailyMed. Retrieved 27 February 2021.
- ^ "Baqsimi EPAR". European Medicines Agency. 17 October 2019. Retrieved 27 February 2021.
- ^ Cite error: The named reference
Ogluo EPARwas invoked but never defined (see the help page). - ^ "Ogluo Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ a b British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 487. ISBN 9780857111562.
- ^ a b c d e f g h "Glucagon". The American Society of Health-System Pharmacists. Archived from the original on 26 December 2016. Retrieved 8 December 2016.
- ^ Cite error: The named reference
FDA PR 20190724was invoked but never defined (see the help page). - ^ "Glucagon (GlucaGen) Use During Pregnancy". www.drugs.com. Archived from the original on 27 December 2016. Retrieved 27 December 2016.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "FDA Approves First Generic of Drug Used to Treat Severe Hypoglycemia". U.S. Food and Drug Administration (FDA) (Press release). 28 December 2020. Retrieved 28 December 2020.